Literature DB >> 3799638

Familial ovarian carcinoma. Clinical nuances.

H T Lynch, C Bewtra, J F Lynch.   

Abstract

Familial ovarian carcinoma has been recognized with increased frequency during the past decade commensurate with physician attention to family history. Putative autosomal dominant inheritance of this heterogeneous problem mandates attention to both paternal and maternal lineages. A family with probable paternal transmission of breast/ovarian carcinoma is presented. One family member had findings consonant with papillary serous adenocarcinoma of ovarian origin, which may have arisen directly from extra-ovarian pelvic mesothelium. These and other clinical nuances of familial ovarian carcinoma are discussed in order to aid physicians in understanding the natural history, surveillance, and management of familial ovarian carcinoma.

Entities:  

Mesh:

Year:  1986        PMID: 3799638     DOI: 10.1016/0002-9343(86)90411-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  Ovarian and cervical cancer.

Authors:  C Williams
Journal:  BMJ       Date:  1992-06-06

2.  Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.

Authors:  E Steichen-Gersdorf; H H Gallion; D Ford; C Girodet; D F Easton; R A DiCioccio; G Evans; M A Ponder; C Pye; S Mazoyer
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

3.  Cancer incidence in the first-degree relatives of ovarian cancer patients.

Authors:  A Auranen; E Pukkala; J Mäkinen; R Sankila; S Grénman; T Salmi
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

4.  Microsatellite instability in ovarian neoplasms.

Authors:  B L King; M L Carcangiu; D Carter; M Kiechle; J Pfisterer; A Pfleiderer; B M Kacinski
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

5.  Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Authors:  R I Olivier; M van Beurden; M A C Lubsen; M A Rookus; T M Mooij; M J van de Vijver; L J van't Veer
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.